Peptide Library

Human study PLS-00187

MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.

Other design · 70 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.primary · Oncogene · 2003-09-01 · PMID 12970751 · DOI

Design and participants

Design
Other design
Population
Patients with early-stage (stage I) non-small cell lung cancer whose resected tumours did or did not metastasize
Conditions
Non-small cell lung cancer
Planned enrollment (registry)
Not reported
Enrolled
70
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per publication type); funder not named in record

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): MALAT-1 and thymosin beta4 expression were associated with metastasis and were prognostic for survival in stage I NSCLC. The authors say this helps identify high-risk patients and highlights the role of noncoding RNAs in cancer.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: The study measures endogenous thymosin beta4 expression in lung tumours as a prognostic marker. It gives no information on administering the compound.
    • abstract only: Only the PubMed abstract is available, so methods and details of sample selection cannot be appraised.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 12970751, abstract (sentences 9-10) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 12970751, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 12970751, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 12970751, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).